Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…Abstract Number: 0800 • ACR Convergence 2021
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…Abstract Number: 1204 • ACR Convergence 2021
CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis
Background/Purpose: In a cohort of early rheumatoid arthritis (eRA) patients, we recently showed that early and aggressive treatment led to remission and limited erosive progression…Abstract Number: 1381 • ACR Convergence 2021
Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…Abstract Number: 1736 • ACR Convergence 2021
Treatment of Lupus Nephritis with Belimumab Is Associated with Reduction in Urinary CD23
Background/Purpose: Urine proteomic approaches have shown promise in identifying dynamic biological pathways in lupus nephritis (LN) which are not captured on renal histopathology or by…Abstract Number: 0323 • ACR Convergence 2021
Ro Positivity Is an Under‐Recognised Poor Prognostic Marker in Systemic Lupus Erythematosus Patients
Background/Purpose: Antibodies to Ro60 (SSA) or Ro52 (SSB) have been described as one of the defining autoantibodies in Sjogren syndrome but they are also commonly…Abstract Number: 0442 • ACR Convergence 2021
Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis
Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…Abstract Number: 0848 • ACR Convergence 2021
Automatic Hand Segmentation from Hand X-rays Using Minimized Training Samples and Machine Learning Models
Background/Purpose: In many hand osteoarthritis (OA) studies (e.g., automatic Joint Space Width measuring), accurate hand segmentation is the first step towards making further analysis. However,…Abstract Number: 1206 • ACR Convergence 2021
Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular synovitis and frequent occurrence of autoantibodies, playing a central role in disease progression. Anti-citrullinated peptide antibodies (ACPA)…Abstract Number: 1384 • ACR Convergence 2021
A Genomic Meta-Analysis of Clinical Variables and Association with Intrinsic Molecular Subsets in Systemic Sclerosis
Background/Purpose: Four intrinsic molecular subsets (Inflammatory, Fibroproliferative, Limited, Normal-like) have been identified in systemic sclerosis (SSc) that may have different clinical associations. To test this…Abstract Number: 1737 • ACR Convergence 2021
Reduction in Urinary CD163 Is Associated with Treatment Response in the Belimumab Lupus Nephritis Trial
Background/Purpose: Urinary CD163 is a macrophage marker which correlates with histological activity index and response to treatment in lupus nephritis (LN), as evidenced by urine…Abstract Number: 0325 • ACR Convergence 2021
A Multianalyte Assay Panel with Cell-bound Complement Activation Products Demonstrates Clinical Utility for the Diagnosis and Treatment of Systemic Lupus Erythematosus
Background/Purpose: The multianalyte assay panel (MAP) consists of cell-bound complement activation products (CB-CAPs) with lupus and non-lupus autoantibodies combined in an algorithm (Dervieux et al.,…Abstract Number: 0449 • ACR Convergence 2021
Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis
Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…Abstract Number: 0868 • ACR Convergence 2021
Cell-bound Complement Activation Products (CB-CAPs) Predicts Type 1 SLE Activity
Background/Purpose: SLE is a multisystem autoimmune disease that displays diverse manifestations that can be categorized into two broad types. Type 1 SLE activity includes inflammatory…Abstract Number: 1207 • ACR Convergence 2021
A Systematic Review Looking at the Relationship Between Serum Calprotectin and Ultrasound Parameters in Rheumatoid Arthritis
Background/Purpose: Serum Calprotectin level has been shown to correlate with disease activity, ultrasound (US) parameters, treatment response and clinical remission in rheumatoid arthritis (RA). The…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 96
- Next Page »